NCT02141438 2025-10-16
REASSURE
Bayer
Completed
Clinical Trials
20 trialsNCT02803437 2025-07-10
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Bayer
Completed
NCT04232761 2024-07-17
RAPIT
Bayer
Completed
NCT04587427 2024-03-08
DIRECT
Bayer
Completed
NCT03315260 2024-02-08
Treatment Satisfaction With Ra-223 in Japan
Bayer
Completed
NCT04256993 2024-01-16
PRECISE
Bayer
Completed
NCT04681144 2023-10-26
QOLRAD
Bayer
Completed
NCT05301062 2023-09-22
CREDIT
Bayer
Terminated
NCT04281147 2022-06-23
REACTIVATE
Bayer
Completed
NCT04516161 2022-03-31
EPIX
Bayer
Completed
NCT03896984 2021-12-29
PHENIX
Bayer
Completed
NCT02398526 2021-11-02
PARABO
Bayer
Completed
NCT02450812 2021-11-02
URANIS
Bayer
Completed
NCT03419442 2020-10-22
Multi-academic Center Study of Xofigo Patients
Bayer
Completed
NCT03563014 2020-05-20
BELFIGO
Bayer
Completed
NCT02899104 2020-03-31
Navigant
Bayer
Completed
NCT03325127 2018-10-31
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
Withdrawn
NCT02518698 2018-09-18
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
Bayer
Completed
NCT02729103 2018-01-25
Treatment Patterns in Metastatic Prostate Cancer
Bayer
Completed
NCT02331303 2018-01-23
A Drug Utilization Study of Radium-223 in Sweden
Bayer
Completed